Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Esketamine Cognitive Functioning in Healthy Subjects
NCT02094378Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2014
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of esketamine in major depressive disorder (MDD) and treatment-resistant depression (TRD) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Change from baseline in cognitive functioning measured by the Cogstate Computerized Battery at 6 hours, Change from baseline in cognitive functioning measured by the Karolinska Sleepiness Scale at 6 hours and 1 more. Started Jun 2014; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT02094378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02094378.